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SUI'r1MARY: 1'0 e1ucldate whether lnter1eul<1ns are invol ved 1n vasopressln or 
oxytocln release during cytok1ne-related stressful condi t10ns， we examlned 
the effects of human interleukin-l βand interleukln-6 on plasma vasopressln 
and oxytocln levels 1n rats. Interleukln-lβadm1nlstrllted lntravenously 
stlmulated both the vasopressln and oxytocln secret10n 1n dose-dependent man-
ners. Ne1ther hormone release was observed followlng ln terleukln-6 
admlnlsLrat1on. Pretreatment w1th asplrln slgn1ficantlY attenuated the 
effets of lnterleukln-lβon both the vasopressln and oxytocln levels. 
SC-19220， a prostaglandin E2 receptor antagonlst， dld not affect the 
lnlerleukln-lβ-lnduced lncrease of plasma oxytocln levels， but almost 
completelY abollshed lts effect on plasma vasopressln levels. These results 
suggest that under certa1n stressful condltlons which accompany the 
siJmulat10n of cytoklne production， 1nterleukln-l 1s involved 1n the increace 
of plasma vasopressln and oxytocln levels and， moreover， dlfferent kinds of 
prostaglandlns are suggested to partlclpate 1n these lnterleukln-l-induced 
hormone release. 
AVP and OXY are repo1'ted to increase ln plasma after the 11ve bacterial 
challenge 01' lv adm1nlstratlon of endotoxln (1，2). Under such condltlons， lt 
has been known a1so that several cytoklnes lncrease e1ther 1n the general 
clrculatlon or locally. Among the cytokines， IL-l and IL-6 are suggested to 
be major ones in causlng endocrlne and metabol1c abnormal1 tles associated 
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w1th these cond1tlons (3，4). To ascertaln the posslble ro1es of IL-l and 
IL-6 1n such 1nvaslve stlmu1l-induced elevatlon of plasma AVP and OXY levels， 
we admln1stered rhlL-1βand rhIL-6 lv to consclous 、freely-movingrats and 
observed the changes of plasma AVP and OXY leve1s measured by RIA. 1n 
addltlon， we studied whether PGs medlate cytokine-induced changes of plasma 
AVP and OXY 1evels. 
MATERIALS AND METHODS 
(' ~Iaterla1s and experlmental protocol 
Adult male rats of the Wlstar straln. welghlng 300-350g. were kept under 
a controlled temperature (25 土 1・C)and flxed 11ght-dark schedule (light 
on at 0600 h. off at 1800 h). Food and water were provlded組斗弘tum・
Severa1 days before b100d samp1lng. a silastlc cannu1a was set 1n the right 
atrlum through the jugular vein and a stalnless steel gulde cannu1a (20 G) 
was lmp1anted stereotaxically and secured with dental cement at 0.8 mm pos-
terlor. 1.4 mm lateral. 3.0 mm ventral to the sregma to facilitate injection 
into the rlght lateral ventricle. 
At 1east 12 hours prlor to blood sampllng. which routlne1y began at 0945 
h. cannu1ated animals were moved to a specla1 samp1lng cage ln whlch blood 
could be drawn from the rats under consclous. free1y-movlng condltlons 
w1thout apparent stress throughout the experlmenta1 period (4). Two hours 
before b100d sampl1ng， an lcv lnjection cannula (24 gauge) was inserted 
through the gu1de cannula to place the tlp 1n the anterlor horn of the rlght 
1ateral ventrlcle. 
Blo10g1cal actl v1tles of rhIL-1βand rhIL-6 used 1n thls exper lmen t 
were reported previously (3.5). Aspirln was admlnlstered as a water soluble 
form (Venoplr1n; The Green Cross Corporatlon. Osaka. Japan). The effects of 
PG receptor antagonlsts on cytokine-induced release of AVP and OXY were 
assessed by contlnuous icv adminls tratlon of the following rnater 1a1s: DW 
A868C. a PGD2 receptor (DP receptor) antagonist (6). and SC-19220. a PGE2 
receptor (EP， receptor) antagonlst(7). both of which were generously provlded 
by The Wel1come Foundat10n Ltd. Beckenham. UK. and Searle Research and 
Development， Skokle， IL， respectlvely. 
Cytokines were dissolved ln 0.2 ml of 0.9% sa11ne contalnlng 0.1% bovine 
serum a1bumin and were iv injected through the intra-atrial cannula. Control 
rats for each experlment recelved lv and/or lcv lnjection with on1Y the 
vehlcle. Blood samples (0.6 101) were withdrawn lnto heparlnized syrlnges 
from the same cannula before (-15 and 0 mln) and 15， 30. 60， 90. and 120 mln 
after the lnjectlon of cytokine. B100d samples were lmmedlately cooled on 
ice and then centr1fuged to obtaln the plasma samples (0.25 ml) whlch were 
stored at -20・C untl1 hormone assay. Plasma osmolarlty was a1so determlned 
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by measuring the freezi ng point using the specimen obtained similarly. Red 
cells were resuspended in physiologic saline and returned to the rats after 
each sampling. 
Hormone assay 
After extraction using Sep-Pak C1e, plasma AVP levels were determined by 
HIA using AVP RI A kits purchased from ~litsubishi Petrochemical Co., Ltd., 
Tokyo, Japan (8) . The recovery ratio of synthetic AVP added to rat plasma by 
thi s extraction procedure was 90% and the results were not corrected by this 
value. The minimal detectable quantity of plasma AVP by this assay system 
was 0.6 pg/ml and intra- and in terassay coefficient s of variation were both 
less than 10%. 
Plasma OXY levels were measured by RIA usi ng anti -OXY r abbi t antiserum 
without extraction, as described previously (2). The minimal detectable 
quantity of plasma OXY by this system was 5 pg/ml and intra- and interassay 
coefficients of variation were both less than 10%. 
Statistical analys is 
Statistical analysis was performed by the ANOVA or the repeated measure-
ments ANOVA and subsequent Bonferroni method; p<0.05 was considered t o be 
significant. Results were expressed as the mean ± SEM of 5 rats. 
RESULTS 
Prior to the measurement of the hormone levels , a couple of preliminary 
experiments were performed to evaluate the validity of experimental system. 
First , we measured tl1e levels of plasma osmolarity and found that osmolarity 
showed only minimal changes throughout the sampling period even in the rats 
which received the highes t dose of rh!L-1 f3, that is, the mean ( ± SEM) 
basal level at 0 min and the maximal level at 60 min were 292 ± 0.8 and 294 
± 1. 0 mOsmol/ kg, respect! vely. Second, we observed the changes of blood 
pressure during the IL-l f3 challenge and ascertained that iv administration 
of rh!L-1 f3 did not signifi cantly change the systemic ~rterial pressure even 
at the highest dose of 10 p g (Figure 1). 
Effects of rhiL-1/3 and rh!L- 6 administrated iv on plasma AVP and OXY 
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levels were assessed after these preliminary experiments. As shown in Figure 
2, rhlL-1 /3 significantly elevated both plasma levels of AVP and OXY in 
dose-dependent manners. The minimal amount of rhiL-1 f3 which could elicit 
AVP and OXY increase were 1 /.1. g and maximal plasma AVP and OXY levels were 
usually observed 30 min after the rhiL-1 f3 administration. On the other 
hand, neither AVP nor OXY levels in plasma were affected by the lv 
administration of rhlL-6 even when 10 /.1. g was administered. Both the 
hormone levels of vehicle-injected control rats showed no significant changes 
during the sampling period. 
~ We next examined the possible Involvement of PGs in IL-1/3 -induced AVP 
and OXY secretion. Effects of a cycl_oxygenase inhibitor, aspirin, and PG 
receptor antagonists, BW A868C and SC-19220, on rhiL-1 f3 -induced elevation 
of plasma AVP and OXY levels were summerized in Figure 3. Aspirin which did 
not alter the basal plasma levels significantly attenuated the rhiL-1 
f3 -induced elevation of both plasma AVP and OXY levels. While lev treatment 
of SC-19220, a EP2 receptor antagonist, completely abolished the rhiL-1 
f3 -induced elevation of plasma AVP level, plasma OXY response to rhiL-1 f3 
did not affected by this treatment. Similar administration of a DP receptor 
antagonist, BW A868C, had no effect on the increase of plasma AVP and OXY 
levels Induced by rhiL-1 /3 • 
DISCUSSION 
Accumulating evidence suggests the existence of bidirectional 
communication between the immune and neuroendocrine system. Among the 
neuroendocr lne changes, t he release of poster lor pituitary hormones during 
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immune or inflammatory processes has not yet been well examined. Recently, 
IL- l and IL-6, which play similar roles In many metabolic responses to acute 
phase inflammatory reactions (9,10), were reported to show similar 
stimulatory effects on the hypothalamo-pituitary functions both in vivo and 
in vitro (11). The present study demonstrated that IL-l administered iv 
increased plasma levels of AVP and OXY wl thout apparent changes of plasma 
osmolarity and arterial blood pressure. 011 the other hand, IL-6 has no such 
effects under the same conditions . In 1987, Sapolsky et al reported that 
both AVP and OXY levels in the pituitary portal blood did not significantly 
change after lv administration of IL-l, the amount of which was sufficient to 
cause ACTII release (12). Therefore, the present data are the first 
observation showing that a cytokine does increase the plasma levels of 
posterior pituitary hormones. Our data concerning IL-l are consistent with a 
previous report using an in vitro perifusion experiment (13) and suggest 
that, during inflammation, not IL-6 but IL-l mediates the effects of 
inflammatory reactions on posterior pituitary resulting in t he hormone 
release without either significant hemodynamic or osmolarity change. This 
idea is compatible with the hypothesis that IL-l and IL-6 do not always share 
0 similar actions on the neuroendocrine organs during the acute phase 
inflammatory reaction. 
The present study also suggest that the stimulatory effects of IL-l on 
AVP and OXY secretion are dependent on PG synthesis. PGE2 and PGD2 were 
reported to increase plasma AVP and OXY levels (14) and possible involvement 
of PG as a mediator of IL-l-induced responses of the central nervous system 
has already been postulated (15,16). Our present reports indicated also that 
PGE2 plays an Important role In the AVP release induced by IL-l. In terms of 
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IL-l-induced OXY release, however, neither DP- nor EP ~-receptor antagonist 
showed significant effects. This suggests that PGE2 and PGD2 are not 
involved in IL-l-induced OXY release. PGF2 a , another PG found in the 
brain, might be responsible for the IL-l-stimulated OXY secretion as was 
suggested from the previous report (17). Further study should clarify the 
mediator in IL-l-induced OXY release. 
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Figure 1. Effec ts of iv administration of rhiL-1 /3 (10 JJ. g) on systemic 
arterial blood pressure (SBP, shaded area) and heart rate (IIR, e ) . Rats 
were catheterized in tl1e left femoral vein (for admini s tration of cytokines) 
and femoral artery (for recording blood pressure and heart rate) under the 
halothane anesthesia (2%) with artificial ventilation through a tracheal 
cannula. Each point represents the mean of 3 rats. 
Figure 2. Time- course of the changes of plasma AVP (upper panel) and OXY 
(lower panel) levels in response to iv administration of rhlL-1/3 or rhiL-6. 
The cytokines were administered at the following doses: 
(Q ) : rhiL-1/3 10 JJ.g, ( Q ):rhiL-1/3 1 JJ.g, ( 6 ):rhiL-1/3 0.1 JJ.g, 
( A ) : rhlL-6 10 J1. g, ( e ) :control. Each point rep resents the mean ± SEM of 
5 rats . •:p<0.05 compared to the control rats. 
Figure 3. Effects of aspirin, BW A868C or SC-19220 on the changes of plasma 
AVP (upper panel) and OXY (lower panel) levels induced by rhiL-1/3. Aspirin 
was administered 30 min and immediately before the rhiL-1 /3 administration 
at a dose of 100 mg/kg for each injection . Continuous lev administration of 
BW A868C or SC-19220 was started 120 min before the cytoklne injection and 
continued throughout the sampling per lod at the doses of 10 JJ. g/kg/min and 
50 ng/kg/min, respectively, which are reported to be effective in in vivo 
experiments ( 6, 7). ~laxlmal values of these hormone levels were usually 
observed 30 min after the cytoklne injection. Each column represents the 
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